301257 SMO Clinplus
- 45.11
- -0.57-1.25%
SMO Clinplus News
Prius (301257) 2023 Annual Report and 2024 Quarterly Report Review: Innovative Drug Acceptance Capacity Enhances and Gross Margin Continues to Improve
Incident: The company released the 2023 annual report and 2024 quarterly report results announcements, of which: 1) The company achieved operating income of 760 million yuan (YOY +29.65%) in 2023; achieved a net profit of 1.35 million yuan (YOY +29.65%) in 2023; achieved a net profit of 1.35 million yuan
Prius (301257): Performance exceeds expectations, core competitiveness continues to improve
Incident: The company released its 2023 annual report and 2024 quarterly report: in 2023, the company achieved revenue of 760 million yuan, an increase of 29.65%; net profit to mother was 135 million yuan, an increase of 86.06% year on year; deducted not returned to mother
Prius (301257) Company Information Update Report: Outstanding performance in 2023, steady growth in new orders
Outstanding performance, with abundant orders providing a guarantee for future performance growth. In 2023, the company achieved operating income of 760 million yuan, an increase of 29.65% over the previous year; net profit to mother was 135 million yuan, an increase of 86.06% over the previous year; deducted
Prius (301257): New orders are growing steadily, and comprehensive strength is constantly being strengthened
Incident: Prius publishes its 2023 Annual Report and 2024 Quarterly Report. The company achieved revenue of 760 million yuan in 2023 (+29.65% YoY) and net profit of 135 million yuan to mother (+86.06% YoY)
Prius (301257.SZ) announced its 2023 annual results, with net profit of 135 million yuan, an increase of 86.06% over the previous year
Prius (301257.SZ) released its 2023 annual report. The company achieved operating income of 7.6 during the reporting period...
Express News | Prius: Net profit of 22.7372 million yuan for the first quarter decreased 10.22% year on year
The A-share diet pill concept fluctuated higher. Kanghui Pharmaceutical went up and down, Kangpeng Technology rose more than 6%, and Nanowei Technology, Haoyuan Pharmaceutical, Medici, and Prius followed suit.
The A-share diet pill concept fluctuated higher. Kanghui Pharmaceutical went up and down, Kangpeng Technology rose more than 6%, and Nanowei Technology, Haoyuan Pharmaceutical, Medici, and Prius followed suit.
Express News | Prius: Shareholders' view is that Zhaotai plans to reduce its holdings by no more than 2%
Prius (301257.SZ): Actual controller Lai Chunbao completed an increase of 160,000 shares
Gelonghui, Feb. 7 | Prius (301257.SZ) announced that as of the announcement disclosure date, the company's chairman and actual controller Mr. Lai Chunbao's plan to increase his holdings had been completed. On February 7, 2024, Mr. Lai Chunbao increased his holdings of the company's shares by 160,000 shares through centralized bidding through the Shenzhen Stock Exchange trading system, accounting for 0.26% of the company's total share capital. The increase in holdings was 6,544,987 yuan (not including transaction fees). The increase amount of the above holdings increase entity has exceeded the lower limit of the amount of the plan to increase their holdings.
The actual controller of Prius (301257.SZ) plans to spend 5 million yuan to 8 million yuan to increase its holdings
Prius (301257.SZ) issued an announcement. Lai Chunbao, the actual controller of the company, plans to increase his holdings from the date of the announcement of this plan...
Prius (301257): Performance is expected to maintain high growth in line with expectations
Event: The company released its 2023 performance forecast. According to the company's forecast, the company expects a profit of 123-146 million yuan in 2023, an increase of 69.86%-101.63% over the same period last year, and is expected to deduct non-profit
Prius (301257.SZ): 2023 net profit pre-increased by 69.86% to 101.63%
Glonghui, January 22丨Prius (301257.SZ) announced its 2023 annual results forecast. Net profit profit attributable to shareholders of listed companies during the reporting period was 123.0 million yuan to 140.6 million yuan, an increase of 69.86% to 101.63% over the same period of the previous year; net profit profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 10,400.00 million yuan to 124.0 million yuan, an increase of 55.41% to 85.30% over the same period last year. In 2023, the company closely revolves around the established development strategy, takes stability and progress as the general tone, and is active
Prius (301257): SMO industry leader empowers clinical research and development
Focus on the SMO field to enable clinical research and development. Prius is a leading domestic SMO company that can provide customers with one-stop clinical trial site management outsourcing services. As of 2023Q3, the company has participated in more than 2,800 countries and countries
Prius (301257. SZ) was reduced by shareholder Huiqiao Hongjia by a total of 1,8292 million shares
Prius (301257.SZ) announced that the implementation of the company shareholder Huiqiao Hongjia's equity change plan has been completed, and public holdings have been reduced cumulatively...
Prius (301257): Profit margins are quickly repaired, and annual results can be expected
The incident describes that the company released a performance report for the third quarter of 2023. In the first three quarters, it achieved operating income of 544 million yuan, an increase of 35.53% over the previous year; achieved net profit of 101 million yuan, an increase of 164.05% over the previous year; in fact
Prius (301257): A leading SMO company that has taken advantage of the rapid growth of the industry
Investment points: The company is a leading SMO enterprise in China. It has advantages in talent team, academy coverage, project experience, etc., and is expected to fully benefit from the expansion and concentration of the SMO industry. Exclusive for leading professional SMO enterprises in China
Prius (301257.SZ): Equity distribution for the first three quarters of 2023, 10 allocations of 0.68 yuan, stock registration date: December 8
Glonghui (301257.SZ) announced on December 1, Prius (301257.SZ) announced that the company's equity distribution plan for the first three quarters of 2023 is to distribute RMB 0.68,0000 in cash (tax included) for every 10 shares to all shareholders based on the company's current total share capital of 61,160,000 shares. The share registration date for the current equity distribution is December 8, 2023, and the day before interest is December 11, 2023.
Prius (301257.SZ) shareholders Hongrun Yingke and Zhang Jing reduced their holdings of the company by 5.46%
Prius (301257.SZ) issued an announcement. Recently, the company received separate notices from shareholders Hongrun Yingke and Zhang Jing...
Price (301257) Company Information Update Report: Steady and Sufficient Revenue Growth, Order Guarantee Continued High Growth in Future Performance
Revenue growth is steady, and sufficient orders guarantee continued high growth in future performance. In the first three quarters of 2023, the company achieved revenue of 544 million yuan (+35.53%) and net profit of 101 million yuan (+164.05%).
Price (301257) 2023 Third Quarter Report Results Announcement Comment: The increase in net profit of the mother exceeds expectations, and various expense rates have further improved
Event: The company released its 2023 three-quarter report, and achieved operating income of 540 million yuan (YOY +35.5%) in the first three quarters; net profit of 100 million yuan (YOY +164.1%); net profit of 0.86 after deduction of non-return net profit
Analysis
Price Target
No Data
